Related Experiment Videos
Eudesmane and megastigmane glucosides from Laggera alata
Qunxiong Zheng1, Zhaojun Xu, Xianfeng Sun
1Department of Traditional Chinese Medicine and Natural Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310031, China.
Phytochemistry
|July 25, 2003
Summary
Researchers isolated five new eudesmane and megastigmane glucosides, alatosides A-E, from Laggera alata. Their structures were determined, suggesting diverse biogenetic pathways for these natural products.
Area of Science:
- Natural Product Chemistry
- Phytochemistry
- Organic Chemistry
Background:
- Laggera alata is a plant species known to produce various secondary metabolites.
- Eudesmane and megastigmane derivatives are classes of natural products with diverse biological activities.
- Understanding the chemical diversity and biosynthesis of plant-derived compounds is crucial for drug discovery.
Purpose of the Study:
- To isolate and characterize new eudesmane and megastigmane glucosides from Laggera alata.
- To elucidate the chemical structures of the isolated compounds using spectroscopic and chemical methods.
- To investigate the potential biogenetic pathways of these secondary metabolites within the Laggera genus.
Main Methods:
- Isolation of compounds from the BuOH fraction of Laggera alata.
- Structure elucidation using a combination of chemical and spectroscopic techniques (e.g., NMR, Mass Spectrometry).
- Comparison with known compounds to identify novel structures.
Main Results:
- Four new eudesmane glucosides (alatosides A-D) and one megastigmane glucoside (alatoside E) were isolated.
- The structures of alatosides A-E were fully characterized.
- Six known compounds were also identified in the extract.
Conclusions:
- The isolation of novel eudesmane and megastigmane glucosides expands the known chemical diversity of Laggera alata.
- The structural features of the isolated compounds provide insights into the biosynthesis of these natural products.
- It is proposed that Laggera species may possess at least two distinct biogenetic pathways for eudesmane derivatives.